Share this article
Share this article
BEIJING, Feb. 24, 2021 /PRNewswire/ Berry Oncology Corporation, the shareholding subsidiary of Berry Genomics, announced the results of a case-control study on the effectiveness of a novel diagnostic method for detecting hepatocellular carcinoma (HCC) in patients with liver cirrhosis, demonstrating the new model had greater accuracy and sensitivity compared to existing screening methods.
The study, published in Cell Research, featured both China and the U.S.-based authors and research teams led separately by Prof. Hong-Yang Wang of the National Center for Liver Cancer, Prof. Jin-Lin Hou of Nanfang Hospital, Southern Medical University and Dr. Lin Wu and Dr. Jian Bai of Berry Oncology. The researchers collected cell-free DNA (cfDNA) samples from a total of 3,234 individuals, including 2,250 patients with liver cirrhosis (LC), 508 with HCC, and 476 healthy controls (CTRL) from 13 hospitals in 11 provinces in China.
19 5亿！九牧30周年敬献史诗级全民狂欢盛宴 -千龙网·中国首都网 qianlong.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from qianlong.com Daily Mail and Mail on Sunday newspapers.
Fuqing celebrates 30 years of great achievement 29th December 2020
AsiaNet 87423
Fuqing, China, Dec. 29, 2020 (Antara/Xinhua-AsiaNet) - On December 26, 1990, Fuqing, previously a county, was approved as a county-level city of Fuzhou by the State Council. Fuqing has since entered a new historical era, embarking on a glorious development journey.
Now ranking the 15th among the top 100 counties in the country and the 2nd in the province of Fujian, Fuqing has developed into a strong industrial city from a large agricultural county, with the regional GDP increased by about 95 times over the past three decades. Continuing a strong momentum of development this year, the city is ranked first in the city of Fuzhou in the evaluations of project-driven, leapfrogging development and investment attraction.